Stephanie A. Christenson, MD, MAS, discusses advancements in COPD research to be presented at ATS 2024. Updates from clinical trials, particularly regarding biologics and biomarker data related to COPD heterogeneity, will be among the expected offerings. In addition, new approaches to the etiology of COPD in the wake of a Lancet Commission statement will be presented, such as understanding the role of environmental exposures.
Dr Christenson is also eager to explore the significance of studying early COPD development, aiming to redirect focus toward disease modification rather than late-stage treatment. Additionally, she anticipates new insights from research on immune responses, COPD biology, epidemiology, and translational studies.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ATS 2024: Exciting Prospects in COPD Research - Medscape - May 07, 2024.
Comments